Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-P59 in outpatients with mild to moderate SARS-CoV-2 infection
NCT04602000Phase 3Completed
- Sponsor
- Celltrion
- Start
- Oct 2020
- Primary completion
- May 2021
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of regdanvimab in coronavirus disease 2019 (COVID-19), sponsored by Celltrion. Started Oct 2020; status: completed.
02
Drugs
regdanvimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04602000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04602000.